{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "CAPR", "name": "Capricor Therapeutics, Inc.", "url": "https://frontierpicks.com/dossiers/CAPR/", "json_url": "https://frontierpicks.com/dossiers/CAPR.json", "status": "WATCHLIST", "current_conviction": "LOW", "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against its evidence in July 2026. The FDA's action on the narrowed application, due by 22 November 2026, settles the case.", "invalidation_trigger": "A daily close above $20.10, over the 200-day moving average, which would show the market pricing deramiocel's approval as likely. FDA approval of the deramiocel biologics license application by the 2026-11-22 action date would also prove the call wrong.", "catalyst_date": "2026-11-22", "portfolio": null, "pick": null, "themes": [ "rare-disease-gene-therapy" ], "tags": [], "sources": [], "notes": [ "The FDA action date for deramiocel, 2026-11-22, falls on a Sunday; the agency can act on or before that date.", "Capricor reports no product revenue; its value depends on the FDA decision on its single lead product, deramiocel.", "A securities class action filed in August 2026 alleges false statements about deramiocel's clinical data; the allegations are unproven.", "US distribution rights for deramiocel are in dispute with partner NS Pharma, with an arbitration hearing expected to begin in mid-2027." ], "source_links": [ { "title": "Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update", "url": "https://www.capricor.com/investors/news-events/press-releases/detail/359/capricor-therapeutics-reports-third-quarter-2026-financial", "date": "2026-11-10" }, { "title": "StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel", "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-capricor-plunges-as-fda-panel-staff-question-effectiveness-of-lead-candidate-deramiocel/", "date": "2026-08-02" }, { "title": "CAPRICOR THERAPEUTICS, INC. - Form 8-K - FY2026", "url": "https://www.sec.gov/Archives/edgar/data/0001133869/000110465926100071/capr-20260824xex99d1.htm", "date": "2026-08-24" }, { "title": "Capricor's PDUFA date for FDA to review Deramiocel has been extended to November 22, 2026", "url": "https://cureduchenne.org/research/capricors-pdufa-date-for-fda-to-review-deramiocel-has-been-extended-to-november-22-2026/", "date": null }, { "title": "CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop", "url": "https://www.morningstar.com/news/pr-newswire/20260811ny22954/capr-investor-announcement-capricor-therapeutics-sued-on-behalf-of-investors-to-recover-losses-after-clinical-data-leads-to-64-stock-drop", "date": "2026-08-11" } ], "evidence": [ { "claim": "An FDA advisory committee voted 9-3 that HOPE-3 did not provide substantial evidence of deramiocel's effectiveness; FDA staff cited post hoc changes to the statistical analysis plan.", "source": "GEN StockWatch, 2026-08-02", "as_of": "2026-07-29" }, { "claim": "Hypersensitivity reactions occurred in 42% of deramiocel patients versus 15% on placebo in HOPE-3.", "source": "GEN StockWatch, 2026-08-02", "as_of": "2026-08-02" }, { "claim": "The FDA classed Capricor's BLA amendment as major, moving the action date from 2026-08-22 to 2026-11-22.", "source": "Capricor 8-K, 2026-08-24", "as_of": "2026-08-24" }, { "claim": "Q3 2026 net loss of $42.7M ($0.73/share) and operating expenses of $44.7M versus $26.3M a year earlier; no revenue.", "source": "Capricor Q3 2026 results release and 10-Q, 2026-11-10", "as_of": "2026-09-30" }, { "claim": "Cash, equivalents, restricted cash and marketable securities of $198.5M at 2026-09-30, down from $318.1M at 2025-12-31.", "source": "Capricor Q3 2026 results release, 2026-11-10", "as_of": "2026-09-30" }, { "claim": "The FDA's July 2026 bioresearch monitoring inspection of the trial ended with a Form 483 listing one observation; FDA feedback on Capricor's response is pending.", "source": "Capricor Q3 2026 results release, 2026-11-10", "as_of": "2026-11-10" }, { "claim": "HOPE-3, published in The Lancet in July 2026, showed slower upper-limb decline on PUL 2.0 with p=0.029.", "source": "Capricor Q3 2026 results release, 2026-11-10", "as_of": "2026-11-10" }, { "claim": "Jones Trading upgraded Capricor to Buy with a $25 price target.", "source": "Jones Trading rating action, 2026-11-11", "as_of": "2026-11-11" } ], "view_changes": [], "frame": null, "filed_numbers": { "as_of": "2026-11-13", "sector": "Healthcare", "financials": { "status": "ok", "reason": null, "close_date": "2026-11-13", "latest_quarter": "2026-09-30", "figures": { "revenue": { "status": "not reported" }, "gross_margin": { "status": "not reported" }, "operating_margin": { "status": "not available" }, "pretax_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": -42.7 }, "net_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "four_quarters_end": "2026-09-30", "value_musd": -42.7, "four_quarters_musd": -147.5 }, "operating_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "first_end": "2025-12-31", "value_musd": -120 }, "capital_spending": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "first_end": "2025-12-31", "value_musd": 12.7 }, "free_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "first_end": "2025-12-31", "value_musd": -132.7 }, "diluted_share_change": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "base_end": "2025-09-30", "pct": 27.2 }, "cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 197.6 }, "debt": { "status": "not available" }, "net_cash": { "status": "not available" }, "deferred_revenue": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 12, "yoy_pct": 0 }, "backlog": { "status": "not reported" }, "receivables": { "status": "not reported" }, "inventory": { "status": "not reported" }, "equity": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-10", "value_musd": 209.8 }, "market_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-09", "basis_filed": "2026-11-10", "value_musd": 554.1 }, "enterprise_value": { "status": "not available" }, "ev_sales": { "status": "not available" }, "ev_ebit": { "status": "not available" }, "pe": { "status": "not meaningful" }, "pb": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-09", "basis_filed": "2026-11-10", "multiple": 2.6 }, "fcf_yield": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-11-09", "basis_filed": "2026-11-10", "pct": -23.9 } } }, "short_interest": { "status": "ok", "settlement": "2026-10-15", "published": "2026-11-13", "short_pct_of_outstanding": 34.16, "days_to_cover": 6.6, "change_pct": 5.5 }, "insiders": { "status": "ok", "as_of": "2026-11-14", "windows": [ { "days": 90, "status": "ok", "from": "2026-08-17", "bought_usd": 0, "sold_usd": 0, "bought_unpriced": 0, "sold_unpriced": 0 }, { "days": 365, "status": "ok", "from": "2025-11-15", "bought_usd": 0, "sold_usd": 8366256.1, "bought_unpriced": 0, "sold_unpriced": 0 } ] } }, "body_markdown": "## Current Thesis\nCapricor Therapeutics' shares are more likely to lag the S&P 500 over the next three months than to lead it. The company has no revenue. Its value rests on one FDA decision on deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). On 2026-07-29, an FDA advisory committee voted 9-3 that the main trial behind deramiocel did not show it works. The FDA's action date of 2026-11-22 settles the case.\n\nSince the vote, Capricor has narrowed its request. In August 2026 it amended the biologics license application (BLA). The amendment added two-year open-label data and asked for a narrower label: upper-limb impairment in patients older than 9, according to the company's 2026-11-10 results release. The FDA classed the amendment as major, which moved the action date from 2026-08-22 to 2026-11-22 (company 8-K, 2026-08-24).\n\nFDA staff did not object to missing data. They objected to post hoc changes in the trial's statistical analysis plan, including how the endpoints were defined (GEN, 2026-08-02). Open-label data has no placebo group, so in this analyst's view it answers that objection only in part.\n\nThe shares closed at $11.22 on 2026-11-11. That close is 166.5% above three months earlier and 72.2% below the 52-week intraday high of $40.37 set on 2025-12-03. At that price, the market is assigning a partial chance of approval. The rating is Low because the outcome is binary and both the FDA's reviewers and its outside panel have already called the evidence insufficient. An approval would prove the call wrong.\n\n## Bull Case\n- **Peer-reviewed data shows a significant effect.** In July 2026, The Lancet published the HOPE-3 trial. It showed slower decline in upper-limb function on the Performance of the Upper Limb scale (PUL 2.0), with p=0.029 (company release, 2026-11-10).\n- **Two-year open-label data shows a lasting effect.** Patients who switched from placebo to deramiocel declined 1.56 points less on PUL 2.0 than in their placebo year, a 76% slowing. Capricor presented the data at the World Muscle Society congress in October 2026 (company release, 2026-11-10).\n- **Cash lasts past the decision.** Cash, equivalents, restricted cash and marketable securities totalled $198.5 million at 2026-09-30. The company sold no shares under its at-the-market program from 2026-01-01 through 2026-11-10 (company release, 2026-11-10).\n- **An analyst upgrade came after the report.** Jones Trading upgraded the shares to Buy with a $25 target on 2026-11-11. The stock closed at $11.22 that day, against $8.87 on 2026-11-10.\n- **An approval could bring a voucher worth cash.** Deramiocel's Rare Pediatric Disease designation may qualify Capricor for a priority review voucher if it is approved. The company's financial outlook excludes any sale of one (company release, 2026-11-10).\n\n## Bear Case\n- **The FDA panel and staff rejected the evidence.** The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 on 2026-07-29 that HOPE-3 did not provide substantial evidence of effectiveness. Staff pointed to post hoc changes to endpoint definitions, analysis methods and the handling of missing data (GEN, 2026-08-02).\n- **Safety and blinding questions remain open.** Hypersensitivity reactions occurred in 42% of deramiocel patients against 15% on placebo. FDA staff said the different side-effect profiles could have let investigators work out who was on the drug (GEN, 2026-08-02).\n- **A trial inspection left one open observation.** The FDA's bioresearch monitoring inspection of the trial in July 2026 ended with a Form 483 listing one observation. Capricor has responded and is waiting for FDA feedback (company release, 2026-11-10).\n- **Costs are rising with no revenue.** Third-quarter 2026 operating expenses were $44.7 million, against $26.3 million a year earlier. The net loss was $42.7 million, or $0.73 a share. Cash fell from $318.1 million at 2025-12-31, and the company cut about 10% of its staff in the quarter (company release, 2026-11-10).\n- **The US sales partner is in a dispute.** Capricor withdrew its motion for a preliminary injunction against its distribution partner NS Pharma and is pursuing arbitration. A hearing is expected to begin in mid-2027 (company release, 2026-11-10). Total liabilities rose to $120.6 million at 2026-09-30 from $50.2 million at 2025-12-31.\n\n## Setup & Price Structure\nThe shares closed at $11.22 on 2026-11-11, after $8.87 on 2026-11-10 and $9.85 on 2026-11-09. Closes between 2026-11-04 and 2026-11-11 ranged from $8.60 to $11.22.\n\nAs of the 2026-11-11 close, the 50-day moving average was $8.09 and the 200-day moving average was $20.08. The shares sit above the 50-day average and well below the 200-day, which still includes prices from before the panel.\n\nThe 52-week closing low is $3.85, set on 2026-07-31, the last session of the week the FDA briefing documents came out and the panel voted. The close three months earlier was $4.21 on 2026-08-13.\n\nIn this analyst's view, the action date decides which level comes next. A complete response letter (a rejection) would bring the July and August closes back into view. An approval would bring the 200-day average and Jones Trading's $25 target into view.\n\n## Catalyst Calendar\n\n- **2026-11-22:** FDA action date for the deramiocel biologics license application (narrowed to upper-limb impairment in DMD patients over 9). An approval would prove the lag call wrong. A complete response letter would leave Capricor with no approved product, $198.5 million of cash at 2026-09-30, and rising costs.\n\n## What Would Change Our Mind\n\nA daily close above $20.10, over the 200-day moving average, which would show the market pricing deramiocel's approval as likely. FDA approval of the deramiocel biologics license application by the 2026-11-22 action date would also prove the call wrong.\n\n## Correlation Notes\nThe shares move on FDA and company news, with little link to the broad market. The largest moves on record came in the week of 2026-07-27, when the FDA briefing documents were released and the panel voted. The latest came on 2026-11-11, the session after the third-quarter report and the day of the Jones Trading upgrade.\n\nUntil the FDA acts, index and biotech-sector moves matter less than news on the review. Once the FDA acts, its decision sets the shares' direction for the rest of the three-month window. A securities class action filed in August 2026 over the company's statements about deramiocel's data adds legal risk that does not depend on the market.", "first_seen": "2026-11-12", "last_analyzed": "2026-11-12T18:05:11+00:00", "last_synthesized": "2026-11-12", "date_modified": "2026-11-12", "license": "Content © FrontierPicks. Cite the canonical URL." }